Department of Orthopedic Surgery and Mayo Clinic, Rochester, Minnesota, USA.
Department of Comparative Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Tissue Eng Part C Methods. 2023 Apr;29(4):154-159. doi: 10.1089/ten.TEC.2023.0008.
AdipoRon is an adiponectin receptor 1, 2 (ADIPOR1 and ADIPOR2) agonist with numerous reported physiological benefits in murine models of human disease, including a proposed reduction in fibrosis. However, AdipoRon has never been investigated in rabbits, which provide a robust model for orthopedic conditions. We examined the safety of intravenous (IV) AdipoRon in New Zealand White (NZW) female rabbits surgically stressed by a procedure that mimics human arthrofibrosis. Fifteen female NZW rabbits were prospectively studied using increasing AdipoRon doses based on established literature. AdipoRon was dissolved in dimethyl sulfoxide (DMSO), diluted in normal saline, and administered IV preoperatively and for 5 subsequent days postoperatively. The primary outcome was overall toxicity to rabbits, whereas secondary outcomes were change in rabbit weights and hemodynamics and defining acid-base characteristics of the drug formulation. Two rabbits expired during preoperative drug administration at 25 mg/kg. Remaining rabbits received preoperative doses of DMSO (vehicle), 2.5, 5, or 10 mg/kg of AdipoRon without complications. On postoperative day 1, one rabbit sustained a tonic-clonic seizure after their second dose of 10 mg/kg AdipoRon. The remaining 12 rabbits (4 in each group) received six serial doses of vehicle, 2.5, or 5 mg/kg of AdipoRon without adverse effects. All formulations of AdipoRon were within safe physiological pH ranges (4-5). We are the first to report the use of IV AdipoRon in a surgically stressed rabbit model of orthopedic disease. AdipoRon doses of 5 mg/kg or less appear to be well-tolerated in female NZW rabbits. Impact statement We provided the first toxicity assessment and dose optimization of a new antifibrotic experimental medication, AdipoRon, in a surgically stressed rabbit model of knee arthrofibrosis.
AdipoRon 是一种脂联素受体 1、2(ADIPOR1 和 ADIPOR2)激动剂,在人类疾病的小鼠模型中具有许多报道的生理益处,包括纤维化减少。然而,AdipoRon 从未在兔子中进行过研究,兔子为骨科疾病提供了一个强大的模型。我们研究了静脉内(IV)AdipoRon 在通过模拟人类关节纤维性强直的手术应激的新西兰白兔中的安全性。15 只新西兰白兔女性前瞻性地接受了基于既定文献的递增 AdipoRon 剂量研究。AdipoRon 溶解在二甲基亚砜(DMSO)中,用生理盐水稀释,在术前和术后 5 天内静脉内给药。主要结果是兔子的总体毒性,次要结果是兔子体重和血液动力学的变化以及确定药物制剂的酸碱特性。两只兔子在术前药物治疗期间 25mg/kg 时死亡。其余兔子接受了 DMSO(载体)、2.5、5 或 10mg/kg AdipoRon 的术前剂量,无并发症。在术后第 1 天,一只兔子在接受第 2 次 10mg/kg AdipoRon 后发生强直阵挛性癫痫发作。其余 12 只兔子(每组 4 只)接受了 6 个连续剂量的载体、2.5 或 5mg/kg AdipoRon,没有不良反应。所有 AdipoRon 制剂均在安全的生理 pH 值范围内(4-5)。我们是第一个报告在骨科疾病的手术应激兔模型中使用静脉内 AdipoRon 的人。5mg/kg 或更少的 AdipoRon 剂量似乎在新西兰白兔中耐受良好。